Streetwise Live! Presents Silver Viper Minerals on 05/12/2021. Learn More

Streetwise Articles



AbbVie's Allergan Aesthetics to Acquire Soliton for $550 Million
Source: Streetwise Reports  (5/10/21)
Soliton Inc. shares traded 25% higher after the company reported it had agreed to be acquired by AbbVie Inc.'s Allergan Aesthetics for $22.60 per share in an all cash transaction. More >


 McAlinden Research Partners

Telehealth's Transformation of Healthcare Will Outlive the Pandemic, Boost AI Applications
Source: McAlinden Research for Streetwise Reports  (5/7/21)
COVID-19 brought record-setting investment to the healthcare industry in 2020, but this year is shaping up to be even better, reports McAlinden Research Partners. Demand for telehealth services skyrocketed during the pandemic, and funding is starting to follow suit.


More >


Virtual Care Solutions Company Adds New Clients, Expands Care Management Team
Source: Streetwise Reports  (5/7/21)
Reliq Health Technologies reported the addition of four new skilled nursing facility customers in the southern U.S. and announced plans to expand its Care Management Team to meet the growing demand for Care Management Services. More >


Twist Bioscience Shares Wind Higher After Firm Posts 62% YoY Increase in Q2 Revenue
Source: Streetwise Reports  (5/7/21)
Shares of Twist Bioscience Corp. traded 14% higher after the firm reported that orders in Q2/21 grew by 69% year-over-year and that it is raising its FY/21 revenue guidance to $121–129 million. More >


Biotech's Gene Therapy Assets Put It 'Ahead of the Pack'
Source: Streetwise Reports  (5/5/21)
Sio Gene Therapies' focus and strategic portfolio are discussed in an H.C. Wainwright & Co. coverage initiation report. More >


Firm Doubles in Size by Adding Four New Psychedelic Mental Health Clinics
Source: Streetwise Reports  (5/5/21)
Novamind Inc. is opening four new psychedelic mental health clinics as part of the company's national expansion strategy, giving it the capability to conduct 65,000 client visits in 2021. More >


BioNTech Shares Gain 11% on Filing COVID-19 Vaccine Expanded Use Request to EMA in Children Ages 12 to 15
Source: Streetwise Reports  (5/3/21)
BioNTech shares established a new 52-week high price after the company reported that together with its partner Pfizer it has filed a request to expand Conditional Marketing Authorization of COMIRNATY® in the EU to adolescents ages 12 to 15 for its mRNA-based SARS-CoV-2 vaccine.
More >


CryoLife Shares Trade 18% Higher on Q1 Financial Results
Source: Streetwise Reports  (4/30/21)
Shares of CryoLife Inc. set a new 52-week high intraday price after the company reported that total revenues in Q1/21 increased by 7% YoY to $71.1 million. More >


Galera Posts Positive Data from Phase 1/2 Pancreatic Cancer Trial
Source: Streetwise Reports  (4/29/21)
Galera Therapeutics shares traded 25% higher after the company reported new data from its Phase 1/2 pilot study of dismutase mimetic GC4419 that when used in combination with radiation therapy was shown to nearly double median overall survival time in patients with locally advanced pancreatic cancer. More >


Biopharma Study Shows Safety of Stem Cell Therapy in Severe COVID-19 Patients
Source: Streetwise Reports  (4/28/21)
The clinical trial, in which Sorrento Therapeutics established safety, and the company's next steps for this potential treatment are summarized in a Dawson James Securities report. More >


Company Receives Its Largest Order for Antibiotic-Free Animal Feed Product
Source: Streetwise Reports  (4/28/21)
Avivagen Inc. reported it received a 4.4 metric tonne purchase order for OxC-beta Livestock from UNAHCO representing its largest single order to date. More >


ADMA Biologics Granted FDA Approval to Boost IVIG Production by 50%
Source: Streetwise Reports  (4/28/21)
ADMA Biologics shares traded 9% higher after the company received FDA approval for increased intravenous immune globulin production scale, allowing the firm to increase manufacturing capacity from 400,000 to 600,000 liters and achieve peak revenues of greater than $300 million. More >


Aldeyra's Drug Meets All Key Endpoints in Phase 3 Allergic Conjunctivitis Trial
Source: Streetwise Reports  (4/27/21)
Aldeyra Therapeutics shares traded 33% higher after the firm reported that reproxalap significantly met all primary and secondary endpoints in its Phase 3 allergic conjunctivitis study. More >


Ocugen Reports $100 Million Direct Share Offering at Market Premium from Institutional Investors
Source: Streetwise Reports  (4/23/21)
Ocugen Inc. shares traded up as much as 47% before closing just 3.66% higher after the company announced a $100 million registered direct offering of common stock priced at a $10 per share, which represents a premium to the market price. More >


Healthcare Services Group Shares Rise 13% on Q1 Earnings and Quarterly Dividend Increase
Source: Streetwise Reports  (4/21/21)
Healthcare Services Group Inc.'s shares traded 13% higher after the company reported Q1/21 financial results that included a 22% YoY increase in net income. More >


Is the Trend Turning for This Psychedelic Stock?
Source: Clive Maund for Streetwise Reports  (4/19/21)
Technical analyst Clive Maund charts Delic Inc. and explains why he considers the stock attractive at this point. More >


Merck Selects Rapidly Growing Psychedelic Medicine Company as Key Research Site
Source: Streetwise Reports  (4/16/21)
Novamind runs clinics, research sites and therapeutic retreats and is positioning itself for expansion. More >


Health Tech Company Acquiring Ontario Health Management Firm, Its Largest Transaction Ever
Source: Streetwise Reports  (4/16/21)
A Research Capital Corp. report discusses CloudMD Software & Services' acquisition of Oncidium, "one of Canada's leading health
management companies." More >


Ardelyx to Receive $5M Milestone Payment as Japan Partner Initiates Phase 3
Source: Streetwise Reports  (4/15/21)
Ardelyx Inc. shares traded 11% higher after Kyowa Kirin Co. Ltd., its collaborative partner in Japan, initiated four Phase 3 clinical trials of tenapanor for treatment of hyperphosphatemia. More >


Biotech Company Acquires Therapeutics Firm, Gains 'Gem' in the Portfolio
Source: Streetwise Reports  (4/14/21)
Dawson James Securities advised it is maintaining its "Buy" rating after Sorrento Therapeutics announced the acquisition of ACEA Therapeutics for $38 million in stock. More >


Novocure Shares Climb 50% on Acceleration of Phase 3 Lung Cancer Trial
Source: Streetwise Reports  (4/13/21)
Novocure Ltd. shares reached a new 52-week high after the company reported an update from its Phase 3 Pivotal LUNAR trial of tumor treating electrical fields in non-small cell lung cancer. More >


Affimed NV Shares Rise 20% on Initial Data from Phase 1 R/R CD30-Positive Lymphoma Trial
Source: Streetwise Reports  (4/9/21)
Affimed NV shares reached a new 52-week high price after the company presented initial data from a Phase 1 trial of its AFM13 that shows potential to help NK cells target and destroy cancer cells. More >


Gene Therapy Restoring Light Sensitivity 'Showed Impressive Dose-Response Improvements'
Source: Streetwise Reports  (4/7/21)
Roth Capital Partners advised that Applied Genetic Technologies co-development of BS01 with Bionic Sight "validates its gene therapy capabilities." More >


Biopharma's Phase 2b/3 Alzheimer's Disease Trial Approved to Continue
Source: Streetwise Reports  (4/7/21)
Anavex Life Sciences' study, its drug's mechanism of action and the company's upcoming catalysts are covered in a Dawson James Securities report. More >


Biohaven Expects Net Revenue of $43.8 Million in Q1 for Its Migraine Medicine
Source: Streetwise Reports  (4/7/21)
Biohaven Pharmaceutical shares traded 10% higher after the company reported that in Q1/21 net product revenue for its migraine drug NURTEC ODT is estimated to be approximately $43.8 million. More >


Showing Results: 1 to 25 of 1797 Next

Notable Quotes

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe